Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | Outperform | William Blair | |
| 5/27/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 10/10/2024 | $13.00 | Buy | UBS |
| 10/9/2024 | $16.00 | Buy | Rodman & Renshaw |
| 7/3/2024 | $8.00 | Neutral | H.C. Wainwright |
| 3/4/2024 | $40.00 | Overweight | Morgan Stanley |
| 3/4/2024 | $39.00 | Overweight | JP Morgan |
| 3/4/2024 | $44.00 | Overweight | Wells Fargo |
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis supports clear and rapid path to BLA Webcast today August 28th, at 11 am ET EMERYVILLE, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, will host a virtual KOL event today to highlight its neuroimmunology CAR T franchise in stiff person syndrome (SPS) and myasthenia gravis (MG). As part of this e
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences: 2025 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, September 3rd, 2025Time: 11:00 a.m. ET Morgan Stanley 23rd Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, September 8th, 2025Time: 4:05 p.m. ET H.C. Wainwright 27th Annual Global Investment ConferenceFormat: Fireside Chat Date: Tuesday, September 9th, 2025T
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended June 30, 2025. "The second quarter was
10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended June 30, 2025. "The second quarter was
Webcast to be held August 28, 2025, 11:00am ET EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss its neuroimmunology franchise. The event will take place on Thursday, August 28, 2025, from 11:00am to 1:30pm ET. Presentations will feature members of the Company's management team and the following renowned KOLs: Srikanth Muppidi, M.D., Stanford MedicineRicardo Grieshaber-Bouyer, M.D., Ph.D., FAU Erlangen-NümbergAiden Haghiki
Dr. Marc Grasso brings more than 25 years of public company, capital markets and investment banking expertise to the role EMERYVILLE, Calif., June 30, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the appointment of Marc Grasso, M.D., as its Chief Financial Officer (CFO), effective today. Dr. Grasso brings more than 25 years of public company, capital markets, and investment banking management experience to the role. He succeeds Ryan Jones, MBA, who will move to a strategic advisor role to ensure a seamless transition.
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)
William Blair initiated coverage of Kyverna Therapeutics with a rating of Outperform
H.C. Wainwright upgraded Kyverna Therapeutics from Neutral to Buy and set a new price target of $5.00
UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00